Differential interaction of GBR 12909, a dopamine uptake inhibitor, with cocaine and methamphetamine in rats discriminating cocaine

No abstract is available for this paper.

• Publication year

  2001

• Venue

  Psychopharmacology

• Publication date

  2001-03-15

• Fields of study

  Medicine, Psychology

• Identifiers
  DOI 10.1007/s002130100684PMID 11401007
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Self-administration of GBR 12909 on a fixed ratio and progressive ratio schedule in rats

  2005cited by this paper
• Modification of behavioral effects of cocaine by selective serotonin and dopamine uptake inhibitors in squirrel monkeys

  2005cited by this paper
• Comparative behavioral pharmacology of cocaine and the selective dopamine uptake inhibitor RTI-113 in the squirrel monkey.

  2000cited by this paper
• Relationships among dopamine transporter affinities and cocaine-like discriminative-stimulus effects

  2000cited by this paper
• Neurochemical neutralization of methamphetamine with high‐affinity nonselective inhibitors of biogenic amine transporters: a pharmacological strategy for treating stimulant abuse

  2000cited by this paper
• Dopaminergic involvement in the discriminative-stimulus effects of methamphetamine in rats

  2000cited by this paper
• Dose-response and duration effects of acute administrations of cocaine and GBR12909 on dopamine synthesis and transporter in the conscious monkey brain: PET studies combined with microdialysis.

  2000cited by this paper
• Cocaine-induced changes in extracellular dopamine determined by microdialysis in awake squirrel monkeys

  2000cited by this paper
• Synthesis and pharmacology of site-specific cocaine abuse treatment agents: 2-(aminomethyl)-3-phenylbicyclo[2.2.2]- and -[2.2.1]alkane dopamine uptake inhibitors.

  1999cited by this paper
• National Survey Results on Drug Use from the Monitoring the Future Study, 1975-1998. Volume I: Secondary School Students.

  1999cited by this paper
• GBR12909 attenuates amphetamine‐induced striatal dopamine release as measured by [11C]raclopride continuous infusion PET scans

  1999influential reference
• The dopamine hypothesis of reward: past and current status.

  1999cited by this paper
• Pharmacotherapies for treatment of cocaine abuse: preclinical aspects.

  1999cited by this paper
• Behavioral and neurochemical effects of the dopamine transporter ligand 4-chlorobenztropine alone and in combination with cocaine in vivo.

  1999cited by this paper
• Drug-activation of brain reward pathways.

  1998cited by this paper
• Drug discrimination in methamphetamine-trained monkeys: agonist and antagonist effects of dopaminergic drugs.

  1998cited by this paper
• Synergism between buprenorphine and cocaine on the rotational behavior of the nigrally-lesioned rat

  1997cited by this paper
• Theory and statistics of detecting synergism between two active drugs: cocaine and buprenorphine

  1997cited by this paper
• Pharmacokinetic and pharmacodynamic analysis of the actions of D-amphetamine and D-methamphetamine on the dopamine terminal.

  1995cited by this paper
• A review of the effects of dopaminergic agents on humans, animals, and drug-seeking behavior, and its implications for medication development

  1995cited by this paper
• Effects of monoamine reuptake inhibitors on cocaine self-administration in rats.

  1995cited by this paper
• Noradrenergic involvement in the discriminative stimulus effects of cocaine in squirrel monkeys.

  1995cited by this paper
• Effects of dopamine reuptake inhibitors on food- and cocaine-maintained responding: I. Dependence on unit dose of cocaine.

  1995cited by this paper
• Dopaminergic correlates of motivated behavior: importance of drive

  1995cited by this paper
• Pharmacological characterization of the novel discriminative stimulus effects of a low dose of cocaine.

  1994cited by this paper
• GBR12909 attenuates cocaine-induced activation of mesolimbic dopamine neurons in the rat.

  1994cited by this paper
• Effects of GBR 12909 and cocaine on cocaine-maintained behavior in rhesus monkeys.

  1993cited by this paper
• Drugs of abuse: anatomy, pharmacology and function of reward pathways.

  1992cited by this paper
• Statistical analysis of drug combinations for synergism.

  1992cited by this paper
• Behavioral effects of selective dopaminergic compounds in rats discriminating cocaine injections.

  1991cited by this paper
• Monoamine reuptake inhibitors enhance the discriminative state induced by cocaine in the rat

  1991cited by this paper
• Characterization of the effects of cocaine and GBR 12909, a dopamine uptake inhibitor, on behavior in the squirrel monkey.

  1991cited by this paper
• Discriminative stimulus effects of cocaine.

  1991cited by this paper
• Interactions of [3H]amphetamine with rat brain synaptosomes. II. Active transport.

  1991cited by this paper
• Pharmacological characterization of the discriminative-stimulus effects of GBR 12909.

  1991cited by this paper
• Effects of cocaine and related drugs in nonhuman primates. III. Self-administration by squirrel monkeys.

  1989cited by this paper
• The dopamine uptake inhibitor GBR 12909: selectivity and molecular mechanism of action

  1989cited by this paper
• The dopamine inhibitor GBR 12909: selectivity and molecular mechanism of action.

  1989cited by this paper
• Chemical release of dopamine from striatal homogenates: evidence for an exchange diffusion model.

  1979cited by this paper
• Evaluation of the discriminative effects of morphine in the rat.

  1976cited by this paper

• 2-Substituted 3β-Aryltropane Cocaine Analogs Produce Atypical Effects without Inducing Inward-Facing Dopamine Transporter Conformations

  2016cites this paper
• Predicting abuse potential of stimulants and other dopaminergic drugs: overview and recommendations.

  2014cites this paper
• Dual dopamine/serotonin treatment approach for addictive behaviour

  2013cites this paper
• Sigma receptors and cocaine abuse.

  2011cites this paper
• Monoaminergic Psychomotor Stimulants: Discriminative Stimulus Effects and Dopamine Efflux

  2010cites this paper
• Discriminative Stimulus and Subject-Rated Effects of Methamphetamine, d-Amphetamine, Methylphenidate, and Triazolam in Methamphetamine-Trained Humans

  2009cites this paper
• Combinations of Cocaine with Other Dopamine Uptake Inhibitors: Assessment of Additivity

  2009cites this paper
• 5-HT1B Receptor-Mediated Serotoninergic Modulation of Methylphenidate-Induced Locomotor Activation in Rats

  2008cites this paper
• Hypothesis-driven medication discovery for the treatment of psychostimulant addiction.

  2008cites this paper
• Neurochemical and Neurobehavioral Consequences of Methamphetamine Abuse

  2007cites this paper
• Intra-VTA CART 55-102 reduces the locomotor effect of systemic cocaine in rats: an isobolographic analysis.

  2007cites this paper
• Pharmacology and Treatments

  2007cites this paper
• Interactions of Cocaine with Dopamine Uptake Inhibitors or Dopamine Releasers in Rats Discriminating Cocaine

  2006cites this paper
• Investigation of the potential pharmacokinetic and pharmaco‐dynamic drug interaction between AHN 1‐055, a potent benztropine analog used for cocaine abuse, and cocaine after dosing in rats using intracerebral microdialysis

  2006cites this paper
• Effects of N-Substituted Analogs of Benztropine: Diminished Cocaine-Like Effects in Dopamine Transporter Ligands

  2004cites this paper
• Behavioral effects of rimcazole analogues alone and in combination with cocaine.

  2003cites this paper
• Differential involvement of 5-HT(2A) receptors in the discriminative-stimulus effects of cocaine and methamphetamine.

  2002cites this paper
• Pharmacokinetic antagonism of (+)-methamphetamine discrimination by a low-affinity monoclonal anti-methamphetamine antibody

  2002cites this paper
• Biochemical and behavioral characterization of novel methylphenidate analogs.

  2002influential citation
• Behavioral effects of cocaine and dopaminergic strategies for preclinical medication development

  2002cites this paper